Sensitive LC-MS/MS approach for the quantification of proteolysis targeting chimeras in a biological matrix
Proteolysis targeting chimeras (PROTACs) are endogenous protein degraders that are capable of removing specific protein targets using a cell’s disposal machinery. PROTACs have recently evolved as a therapeutic modality, with several candidates moving into the clinical trial stage. Understanding the pharmacological response is fundamental during drug discovery and development, given that PROTACs have expressed high potency in nanomolar drug concentrations. Therefore, sensitive and selective assays for high-confidence detection and quantification of PROTACs are needed to ensure safety and efficacy in the drug development pipeline.
In this discussion, we explore a sensitive LC-MS/MS workflow for quantifying PROTACs in a biological matrix using the SCIEX 7500 system.
What will you learn?
- Achieving low-level quantification of PROTACs in a biological matrix with minimal sample preparation
- Reaching high reproducibility and accuracy for the analysis of PROTACs using the SCIEX 7500 system, featuring improved front-end technology
- Increasing productivity with a user-friendly interface and an integrated platform for data acquisition, processing and management for routine bioanalysis using SCIEX OS software
Who may this interest?
- Researchers involved in drug discovery and development
- Drug developers performing pharmacokinetic studies and regulated bioanalysis
Speaker
Ebru Selen
Biologics Applications Scientist
SCIEX, USA
Ebru Selen completed her doctoral degree at the University of Wisconsin-Madison (Wisconsin, USA) before joining the Johns Hopkins School of Medicine (Maryland, USA) to work within biological chemistry for her postdoctoral training. During her academic years, Ebru developed mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy methods to unravel the metabolic roles of well-known but underexplored enzymes and pathways. The results of her projects and collaborative efforts have been published in high-impact journals such as the Journal of Proteome Research, Journal of Biological Chemistry, Cell Reports and Cell Metabolism.
Ebru is currently a Biopharma Application Scientist at SCIEX. She specializes in applying new mass spectrometry technologies in biopharma quantification workflows for both small and large molecules. She is currently collaborating with thought leaders in the pharma and biopharma community to provide solutions to analytical challenges.
This webinar was recorded on Thursday 20 April 2023.
In association with
